Source comparison
MK-677 News 2026: Application Comparison
Bone Mineral Density GH-stimulated osteoblast activity, IGF-1-mediated bone formation High (Phase 2 RCT with 52-week endpoint data) 20–25mg daily Screen for baseline glucose dysregulation; monitor HbA1c every 12 weeks Strongest evidence base; suitable for popu
This comparison does not assign a generated winner or score.
- Bone Mineral Density
- GH-stimulated osteoblast activity, IGF-1-mediated bone formation
- High (Phase 2 RCT with 52-week endpoint data)
- 20–25mg daily
- Screen for baseline glucose dysregulation; monitor HbA1c every 12 weeks
- Strongest evidence base; suitable for populations with osteopenia or fracture risk
- Lean Mass Preservation (Aging)
- IGF-1 upregulation, reduced protein catabolism
- Moderate (observational studies, mechanistic plausibility)
- 15–25mg daily
- Co-administer with resistance training; insufficient as monotherapy
- Modest effect size; better suited as adjunct to exercise intervention
- Metabolic Health (Lipid/Glucose)
- Mixed effects; GH increases lipolysis but also insulin resistance
- Low-Moderate (conflicting endpoints in trials)
- 10–20mg daily with metabolic monitoring
- High risk in pre-diabetic populations; requires continuous glucose tracking
- Not recommended as primary metabolic intervention; lipid benefits offset by glucose elevation risk
- Sleep Quality / GH Pulse Amplitude
- Mimics natural nocturnal GH surge via ghrelin receptor agonism
- Moderate (subjective endpoints, polysomnography data limited)
- 12.5–25mg before sleep
- Minimal if dosing timed appropriately
- Anecdotal support strong; objective sleep architecture data still limited
- Wound Healing / Tissue Repair
- IGF-1-mediated collagen synthesis, angiogenesis
- Low (preclinical models only; no human RCT data)
- Unknown; extrapolated from other GH secretagogue research
- Insufficient evidence for clinical recommendation; investigational stage only